EmblemHealth said it would provide coverage for Senseonics' Eversense continuous glucose monitoring (CGM) system, effective immediately. The move grants Senseonic access to roughly 2.9 million EmblemHealth members in New York, New Jersey, and Connecticut.
Shares of Senseonics Holdings (NYSEMKT:SENS) soared 80.4% on Tuesday after the medical technology company struck a deal with one of the largest nonprofit health plans in the country.